Thanks for the head up on this Fes. I just read Integra's quarterly form 8-K filed with the SEC. Notable they identify (see snapshot) growth driven by Wound Reconstruction & Care... looks like operating theatres are up and running normally, bodes well for PNV as you indicate.
For those interested in a greater insight into US market conditions for healthcare related to PNV, see Integra's full 10-Q quarterly or 8-K summary filed with the SEC here...
Integra Lifesciences Holdings Corp – Filings and Transcripts – BamSEC
Competitors to PNV, page-141
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
-0.090(3.57%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $2.49 | $2.50 | $2.43 | $2.311M | 940.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17100 | $2.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.45 | 5973 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |